Dr. Nagaraju is a veterinarian and immunologist with expertise in the molecular pathogenesis of autoimmune and genetic muscle diseases. He is the Founding Chair and Professor of Pharmaceutical Sciences at Binghamton University, NY. He was recently a tenured Professor of Integrative Systems Biology and Pediatrics at George Washington University School of Medicine and Health Sciences, and Associate Director of the Center for Genetic Medicine Research. There he established and directed the preclinical drug testing facility at the Children’s National Medical Center, which has now been transferred to AGADA Biosciences. Before joining CNMC in 2005, he was an Assistant Professor of Medicine at the Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine. Dr. Nagaraju’s research led to the identification of novel anti-inflammatory and membrane-stabilizing compounds that show efficacy in muscular dystrophy as well as inflammatory disease models. He has led international efforts on the development of standard operating procedures for preclinical efficacy studies. He currently serves as a preclinical expert on the TREAT-NMD Advisory Committee for Therapeutics (TACT) and as a member of the Medical Advisory Committee of Muscular Dystrophy Association and the Scientific Advisory Committee of Cure Duchenne. He also co-founded ReveraGen Biopharma, a biotech company engaged in developing therapeutics for neuromuscular and inflammatory diseases. He currently serves as a consultant for several biotech companies. Dr. Nagaraju has over 100 publications and holds several federal and non-federal grants for translational research on neuromuscular diseases.